spinal cord injury
Conditions
Interventions
Atorvastatin treatment group:Atorvastatin treatment
control:placebo
Sponsors
First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old; 2. The axonal integrity of ASIA grade A injury was identified by DTI; 3. ASIA Grade B-D injury of spinal cord injury; 4. The injured parts of the carina are neck segment, chest segment or waist segment; 5. Within 18h after admission; 6. Able to complete standardized neurological examination according to ISNCSCI standards (including patients using ventilators) willing and able to participate in the follow-up of this study; 7. MRI scan of the injured area excluded tumors, tuberculosis and other lesions; 8. Women who are fertile must have a negative serum beta-HCG pregnancy test or a negative urine pregnancy test.
Exclusion criteria
Exclusion criteria: 1. Severe opportunistic infection or opportunistic tumor; 2. Abnormal blood routine examination (white blood cells < 3×109/L, hemoglobin < 90g/L, neutrophils < 1.5×109/L, platelets < 75×109/L); 3. Have definite liver disease (hepatitis B surface antigen /HCV antibody positive), or abnormal liver function tests (alanine aminotransferase and/or ASpartate aminotransferase exceeding 3 times the upper limit of normal, or total bilirubin exceeding 2 times the upper limit of normal); 4. Renal insufficiency (glomerular filtration rate < 70ml/min or creatinine exceeding the upper limit of normal); 5. Currently suffering from more serious chronic diseases, metabolic diseases (such as diabetes), neurological and psychiatric diseases and neurotransmitter-related diseases (such as epilepsy, Parkinson's disease, etc.), active bleeding, severe hypertension, severe thrombocytopenia, hyperkalemia; 6. Neurological damage caused by other tissues and organs; 7. Severe head injury as defined by the Glasgow Coma Scale score =14 was associated with head CT showing clinically significant abnormalities (only patients with suspected brain injury were considered by the investigators to need head CT); 8. Participated in a clinical trial of another investigational drug or device within the past 30 days; 9. Allergic to atorvastatin or any of its components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AISA; | — |
Secondary
| Measure | Time frame |
|---|---|
| SEP and MEP; | — |
Countries
China
Contacts
Public ContactGuoyong Yin
The First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed